- Home
- HUMA vs TALK Comparison
HUMA vs TALK Comparison
Compare HUMA & TALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUMA
- TALK
- Stock Information
- Founded
- HUMA 2004
- TALK 2012
- Country
- HUMA United States
- TALK United States
- Employees
- HUMA N/A
- TALK N/A
- Industry
- HUMA Biotechnology: Pharmaceutical Preparations
- TALK Medical/Nursing Services
- Sector
- HUMA Health Care
- TALK Health Care
- Exchange
- HUMA Nasdaq
- TALK Nasdaq
- Market Cap
- HUMA 427.2M
- TALK 480.0M
- IPO Year
- HUMA N/A
- TALK N/A
- Fundamental
- Price
- HUMA $1.70
- TALK $2.57
- Analyst Decision
- HUMA Strong Buy
- TALK Buy
- Analyst Count
- HUMA 6
- TALK 5
- Target Price
- HUMA $14.60
- TALK $4.38
- AVG Volume (30 Days)
- HUMA 4.1M
- TALK 2.0M
- Earning Date
- HUMA 03-28-2025
- TALK 05-06-2025
- Dividend Yield
- HUMA N/A
- TALK N/A
- EPS Growth
- HUMA N/A
- TALK N/A
- EPS
- HUMA N/A
- TALK 0.01
- Revenue
- HUMA N/A
- TALK $187,593,000.00
- Revenue This Year
- HUMA N/A
- TALK $23.45
- Revenue Next Year
- HUMA $3,797.96
- TALK $21.15
- P/E Ratio
- HUMA N/A
- TALK $385.88
- Revenue Growth
- HUMA N/A
- TALK 25.02
- 52 Week Low
- HUMA $1.76
- TALK $1.60
- 52 Week High
- HUMA $9.97
- TALK $4.36
- Technical
- Relative Strength Index (RSI)
- HUMA 24.28
- TALK 35.64
- Support Level
- HUMA $1.96
- TALK $2.71
- Resistance Level
- HUMA $3.36
- TALK $2.96
- Average True Range (ATR)
- HUMA 0.24
- TALK 0.12
- MACD
- HUMA -0.11
- TALK -0.00
- Stochastic Oscillator
- HUMA 0.00
- TALK 19.79
Stock Price Comparison Chart: HUMA vs TALK
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
About TALK Talkspace Inc.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.